Xconomy -- Stemgent, a provider of consumable research materials for stem cell scientists, has raised $5.6 million of a planned $10.1 million round of equity funding, according to an SEC filing. The funding includes the conversion of promissory notes. The company, which has offices in Cambridge, MA, and San Diego, previously raised $14 million in March 2009 from HealthCare Ventures and Morgenthaler Ventures.
